AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23735317 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe QDM complex
Number of subjects: 136
Study 20542963 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release (MR) prednisone (2-10 mg/day)
Number of subjects: 288
Study 20542963 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) prednisone
Number of subjects: 288
Study 20542963 — intervention group
Group type: COMPARATOR
Intervention: Both MR and IR groups
Number of subjects: 288
Study 19288904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger-partitioned moxibustion
Number of subjects: 209
Study 19288904 — intervention group
Group type: COMPARATOR
Intervention: Yueyue Shu Granules (control)
Number of subjects: 209
Study 17054466 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (180 mg/day) + Oestradiol (100 microg/24 h for last 10 days)
Number of subjects: 16
Study 17054466 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene (150 mg/day) + Oestradiol (100 microg/24 h for last 10 days)
Number of subjects: 16
Study 17054466 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol (100 microg/24 h for 30 days) + Raloxifene (180 mg/day for last 10 days)
Number of subjects: 16
Study 17054466 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol (100 microg/24 h for 30 days) + Clomiphene (150 mg/day for last 10 days)
Number of subjects: 16
Study 12576315 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg BIRB 796 BS
Number of subjects: 24
Study 12576315 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg BIRB 796 BS
Number of subjects: 24
Study 12576315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10720290 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic T2-hyperintense lesion along the ipsilateral corticospinal tract observed in patients with MS
Number of subjects: 5
Study 10720290 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial inciting event located in the white matter of the superior aspect of the corona radiata
Number of subjects: 5
Study 7933324 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria and tetanus toxoid vaccine (DT) primed infants given PRP-T
Number of subjects: 94
Study 7933324 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria and tetanus toxoid vaccine (DT) primed infants given HbOC
Number of subjects: 94
Study 7933324 — intervention group
Group type: COMPARATOR
Intervention: Control group (unprimed infants) given PRP-T or HbOC
Number of subjects: 94
Study 3064604 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 94
Study 3064604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 29520889 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke leaf extract (ALE) 600 mg daily
Number of subjects: 100
Study 29520889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 28443702 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric supplementation (6 capsules daily for 12 weeks, each containing 500 mg turmeric powder)
Number of subjects: 46
Study 28443702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 capsules daily for 12 weeks)
Number of subjects: 46
Study 27900700 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP supplementation
Number of subjects: 40
Study 27900700 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP group
Number of subjects: 40
Study 27900700 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 27900700 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 22892060 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 378
Study 22892060 — intervention group
Group type: COMPARATOR
Intervention: No HRT (Control)
Number of subjects: 378
Study 21349929 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH tid
Number of subjects: 27667
Study 21349929 — intervention group
Group type: COMPARATOR
Intervention: LMWH
Number of subjects: 27667
Study 21349929 — intervention group
Group type: COMPARATOR
Intervention: UFH bid
Number of subjects: 27667
Study 19615860 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside (SNP)
Number of subjects: 36
Study 19615860 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG)
Number of subjects: 36
Study 19615860 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (SEV)
Number of subjects: 36
Study 19615860 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (SNP, NTG, SEV)
Number of subjects: 36
Study 19615860 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP vs NTG
Number of subjects: 36
Study 19615860 — intervention group
Group type: COMPARATOR
Intervention: SNP vs SEV
Number of subjects: 36
Study 19615860 — intervention group
Group type: COMPARATOR
Intervention: NTG vs SEV
Number of subjects: 36
Study 17908543 — intervention group
Group type: EXPERIMENTAL
Intervention: Helioseal Clear Chroma
Number of subjects: 41
Study 17908543 — intervention group
Group type: EXPERIMENTAL
Intervention: Teethmate F1
Number of subjects: 41
Study 17908543 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric Flow
Number of subjects: 41
Study 14745744 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group intervention
Number of subjects: 60
Study 14745744 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 60
Study 11217590 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine (4 percent with epinephrine 1:100,000)
Number of subjects: 1325
Study 11217590 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (2 percent with epinephrine 1:100,000)
Number of subjects: 1325
Study 9764991 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day for 2 weeks (Group 1)
Number of subjects: 29
Study 9764991 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg twice a week for 2 weeks (Group 2)
Number of subjects: 29
Study 9764991 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg once a week for 2 weeks (Group 3)
Number of subjects: 29
Study 9764991 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg once a week for 12 weeks (Group 4)
Number of subjects: 29
Study 8550361 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 6 mg
Number of subjects: 80
Study 8550361 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 6 mg (second injection)
Number of subjects: 80
Study 8550361 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 6 mg (rescue medication)
Number of subjects: 80
Study 2204432 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (20 mg)
Number of subjects: 0
Study 2204432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 719892 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg vitamin E daily for two weeks
Number of subjects: 45
Study 719892 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 45
Study 31833004 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser irradiation (LLLI)
Number of subjects: 27
Study 31833004 — intervention group
Group type: COMPARATOR
Intervention: Pseudo-laser treatment
Number of subjects: 27
Study 31812472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundus autofluorescence imaging (FAF)
Number of subjects: 90
Study 31812472 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroretinography (ERG) group 3 phenotype
Number of subjects: 90
Study 31812472 — intervention group
Group type: EXPERIMENTAL
Intervention: DAF area quantification
Number of subjects: 90
Study 31812472 — intervention group
Group type: EXPERIMENTAL
Intervention: DAF area
Number of subjects: 90
Study 31812472 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal FAF imaging
Number of subjects: 90
Study 28289815 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-axis ultrasound-guided cannulation
Number of subjects: 190
Study 28289815 — intervention group
Group type: COMPARATOR
Intervention: Long-axis ultrasound-guided cannulation
Number of subjects: 190
Study 25185212 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-25 Hz PPNa stimulation
Number of subjects: 9
Study 25185212 — intervention group
Group type: COMPARATOR
Intervention: 60-80 Hz PPNa stimulation
Number of subjects: 9
Study 23514253 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-age recurrent patients
Number of subjects: 0
Study 23514253 — intervention group
Group type: EXPERIMENTAL
Intervention: Older recurrent patients
Number of subjects: 0
Study 23514253 — intervention group
Group type: COMPARATOR
Intervention: Older nonrecurrent patients
Number of subjects: 0
Study 21812357 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium carbonate 3 x 1 g
Number of subjects: 64
Study 21812357 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer hydrochloride 0.8 g‐‐3 x 2 tabl (3 x 1.6 g)
Number of subjects: 64
Study 21812357 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate 3 x 2 g
Number of subjects: 64
Study 19376184 — intervention group
Group type: EXPERIMENTAL
Intervention: Catecholamine depletion using alpha‐methyl‐para‐tyrosine
Number of subjects: 0
Study 19376184 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 0
Study 16434589 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic counseling intervention arm
Number of subjects: 243
Study 16434589 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 243
Study 16434589 — intervention group
Group type: EXPERIMENTAL
Intervention: Women without cancer at enrollment
Number of subjects: 243
Study 16434589 — intervention group
Group type: EXPERIMENTAL
Intervention: Women found to be BRCA1/2 carriers
Number of subjects: 243
Study 15530754 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 155
Study 15530754 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling + fitness testing
Number of subjects: 155
Study 15530754 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 155
Study 10965439 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimovax vaccine
Number of subjects: 372
Study 9244021 — intervention group
Group type: EXPERIMENTAL
Intervention: First arterial sample (discard volume 4.5 ml)
Number of subjects: 79
Study 9244021 — intervention group
Group type: EXPERIMENTAL
Intervention: Second arterial sample (discard volume 16 ml)
Number of subjects: 79
Study 9244021 — intervention group
Group type: COMPARATOR
Intervention: Venous samples
Number of subjects: 79
Study 7961017 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation (AHF)
Number of subjects: 88
Study 7961017 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (1.7‐2.0 Gy/day, five times/week)
Number of subjects: 88
Study 7961017 — intervention group
Group type: COMPARATOR
Intervention: External RT alone
Number of subjects: 88
Study 3661368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 19
Study 3661368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3661368 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (PE)
Number of subjects: 19
Study 29019860 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Number of subjects: 32
Study 29019860 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 32
Study 27039753 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based smoke-free home program (SFH) implemented in classroom and home over 1 month
Number of subjects: 12
Study 27039753 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 12
Study 22575796 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-mediated cognitive behavioral (GMCB) exercise intervention
Number of subjects: 80
Study 22575796 — intervention group
Group type: COMPARATOR
Intervention: Traditional center-based exercise therapy approach (TRAD)
Number of subjects: 80
Study 22575796 — intervention group
Group type: EXPERIMENTAL
Intervention: GMCB and TRAD interventions
Number of subjects: 80
Study 20841623 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extension training (unilateral knee extension at 80% of 1 repetition maximum, 10 repetitions per set, 4 days/week for 12 weeks)
Number of subjects: 20
Study 20841623 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar flexion training (unilateral plantar flexion at 80% of 1 repetition maximum, 10 repetitions per set, 4 days/week for 12 weeks)
Number of subjects: 20
Study 18952312 — intervention group
Group type: COMPARATOR
Intervention: Exercise only (G2)
Number of subjects: 45
Study 18952312 — intervention group
Group type: COMPARATOR
Intervention: Diet plus exercise (G3)
Number of subjects: 45
Study 18952312 — intervention group
Group type: COMPARATOR
Intervention: Diet only (G4)
Number of subjects: 45
Study 18952312 — intervention group
Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 45
Study 16193898 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoinjector
Number of subjects: 1825
Study 16193898 — intervention group
Group type: COMPARATOR
Intervention: Manual injection
Number of subjects: 1825
Study 13678478 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin extended-release (ER) 500 mg once daily for 5 days
Number of subjects: 351
Study 13678478 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin immediate-release (IR) 250 mg twice daily for 5 days
Number of subjects: 351
Study 10873979 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 141
Study 10873979 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 141
Study 10873979 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 141
Study 10873979 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 141
Study 10873979 — intervention group
Group type: COMPARATOR
Intervention: Overall management
Number of subjects: 141
Study 8860765 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral submandibular gland resection
Number of subjects: 66
Study 8860765 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral submandibular gland resection
Number of subjects: 66
Study 8860765 — intervention group
Group type: COMPARATOR
Intervention: Noncancer control subjects
Number of subjects: 66
Study 1735395 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 15 mg h‐1 infusion (Group I)
Number of subjects: 35
Study 1735395 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group II)
Number of subjects: 35
Study 6336600 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone, 400 mg/d
Number of subjects: 19
Study 6336600 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone, 100 mg/d
Number of subjects: 19
Study 6336600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30723231 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebos provided with a psychological treatment rationale
Number of subjects: 0
Study 29467885 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedaplatin (NDP) plus paclitaxel
Number of subjects: 182
Study 29467885 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (CBP) plus paclitaxel
Number of subjects: 182
Study 27843307 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) supplementation, 3.2 g daily for 6 weeks
Number of subjects: 93
Study 27843307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 24621319 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (1 mg/kg/day up-titrated to 8 mg/kg/day, maximum 500 mg/day)
Number of subjects: 144
Study 24621319 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 144
Study 23194138 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills-based child sexual abuse prevention program (immediate training)
Number of subjects: 46
Study 23194138 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition (delayed training)
Number of subjects: 46
Study 19664156 — intervention group
Group type: EXPERIMENTAL
Intervention: Google search for diagnosis by Investigator A (Consultant with expert knowledge in IM&A)
Number of subjects: 45
Study 19664156 — intervention group
Group type: EXPERIMENTAL
Intervention: Google search for diagnosis by Investigator B (Registrar in IM&A)
Number of subjects: 45
Study 19664156 — intervention group
Group type: EXPERIMENTAL
Intervention: Google search for diagnosis by Investigator C (Research Nurse)
Number of subjects: 45
Study 19664156 — intervention group
Group type: EXPERIMENTAL
Intervention: All investigators combined
Number of subjects: 45
Study 17501980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nobel Direct and Nobel Perfect one-piece implants (OPIs)
Number of subjects: 48
Study 17501980 — intervention group
Group type: COMPARATOR
Intervention: Two-piece implants (TPIs)
Number of subjects: 48
Study 15163440 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 163
Study 15163440 — intervention group
Group type: COMPARATOR
Intervention: Temazepam 20 mg
Number of subjects: 163
Study 11477354 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic live donor nephrectomy
Number of subjects: 70
Study 11477354 — intervention group
Group type: COMPARATOR
Intervention: Open surgical live donor nephrectomy
Number of subjects: 70
Study 10091071 — intervention group
Group type: EXPERIMENTAL
Intervention: EllioStep2
Number of subjects: 416
Study 7835856 — intervention group
Group type: EXPERIMENTAL
Intervention: Capitated payment system (CPS) for continuous patients (N = 201)
Number of subjects: 356
Study 7835856 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial capitation condition for intermittent patients (N = 155)
Number of subjects: 356
Study 7835856 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional fee-for-service care)
Number of subjects: 356
Study 17171884 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 50
Study 17171884 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 50
Study 17171884 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 50
Study 29581202 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-interventional methods for assessing COPD treatment effectiveness
Number of subjects: 3000000
Study 29581202 — intervention group
Group type: COMPARATOR
Intervention: Individual trial data from the TORCH trial
Number of subjects: 3000000
Study 26562679 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of motivational enhancement and cognitive behavioral therapy
Number of subjects: 74
Study 26562679 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment plus additional 'check-up' sessions
Number of subjects: 74
Study 24660157 — intervention group
Group type: EXPERIMENTAL
Intervention: Glide Scope video laryngoscope
Number of subjects: 300
Study 24660157 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 300
Study 23377590 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) for 30 minutes per session, 3 sessions a week, for 12 weeks.
Number of subjects: 40
Study 23377590 — intervention group
Group type: COMPARATOR
Intervention: Usual care (comparison group).
Number of subjects: 40
Study 19896633 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersive OVD (Viscoat)
Number of subjects: 60
Study 19896633 — intervention group
Group type: COMPARATOR
Intervention: Cohesive OVD (Healon GV)
Number of subjects: 60
Study 18178097 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel agents (thalidomide, lenalidomide, bortezomib, dexamethasone)
Number of subjects: 44
Study 18178097 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum levels of angiogenic cytokines
Number of subjects: 44
Study 18178097 — intervention group
Group type: EXPERIMENTAL
Intervention: BM MVD
Number of subjects: 44
Study 15890755 — intervention group
Group type: EXPERIMENTAL
Intervention: HbSS RBCs
Number of subjects: 30
Study 15890755 — intervention group
Group type: COMPARATOR
Intervention: HbAS RBCs
Number of subjects: 30
Study 15890755 — intervention group
Group type: COMPARATOR
Intervention: HbAA RBCs
Number of subjects: 30
Study 14636114 — intervention group
Group type: EXPERIMENTAL
Intervention: Physioball core stability and balance exercises
Number of subjects: 30
Study 14636114 — intervention group
Group type: COMPARATOR
Intervention: Conventional floor exercises
Number of subjects: 30
Study 11116534 — intervention group
Group type: EXPERIMENTAL
Intervention: W. somnifera root powder for 30 days
Number of subjects: 12
Study 8790203 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhenium-186-etidronate (doses ranging from 1295 MBq to 3515 MBq)
Number of subjects: 43
Study 8790203 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 43
Study 1346951 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 27
Study 1346951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 6734920 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicyclomine (Merbentyl)
Number of subjects: 42
Study 6734920 — intervention group
Group type: COMPARATOR
Intervention: Dicyclomine (Merbentyl) + Antacid
Number of subjects: 42
Study 6734920 — intervention group
Group type: COMPARATOR
Intervention: Dicyclomine (Merbentyl) + Placebo
Number of subjects: 42
Study 31557520 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVHDF
Number of subjects: 41
Study 31557520 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 41
Study 29444771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-processed food intake
Number of subjects: 104980
Study 27252426 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN 25 mg plus MTX
Number of subjects: 306
Study 27252426 — intervention group
Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 306
Study 27252426 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 306
Study 27252426 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN reduced-dose group
Number of subjects: 306
Study 24803381 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive (INC)
Number of subjects: 120
Study 24803381 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 120
Study 21279478 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine 800 mg b.i.d for 10 days every month
Number of subjects: 149